FDA to Evaluate Premarket Approval Application for TTFields in Non-Small Cell Lung Cancer
January 19th 2024Application seeks approval for tumor-treating fields therapy combined with either an immune checkpoint inhibitor or docetaxel in patients with metastatic non-small cell lung cancer following progression on or after the use of platinum-based therapy.
Dupixent Gets FDA Label Update in Atopic Dermatitis With Uncontrolled Hand and Foot Involvement
January 16th 2024Trial shows 52% of patients with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement administered Dupixent experienced a clinically meaningful reduction in itch on hands and feet vs. 14% with placebo.
Climbing Health Care Costs Result in Elevated Employer Vigilance
January 16th 2024Soaring healthcare costs show little sign of abating in 2024, and concerns about the affordability of medications and medical services continue to grow, despite investments in technology, clinical innovation, and efforts to manage utilization and waste.
Emergent BioSolutions Awarded Contract to Supply US Military With Anthrax Vaccine
January 12th 2024The US Department of Defense awarded Emergent BioSolutions Inc. with a contract worth up to $235.8 million to supply all branches of the US military with BioThrax (Anthrax Vaccine Adsorbed) for use as pre-exposure prophylaxis against anthrax disease.